Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaGhassan K. Abou‐Alfa, Bruno Sangro, George Lau et al.|NEJM Evidence|2022Cited by 1.4k
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 studyArmando Santoro, Camillo Porta, Lorenza Rimassa et al.|The Lancet Oncology|2012Cited by 550
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.Ghassan K. Abou‐Alfa, Bruno Sangro, Stephen L. Chan et al.|Journal of Clinical Oncology|2022Cited by 398
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trialsGiovanni Fucà, Filippo Pietrantonio, Fotios Loupakis et al.|British Journal of Cancer|2020Cited by 350
Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinomaFrancesca Bernuzzi, Pietro Invernizzi, Francesco Marabita et al.|Clinical & Experimental Immunology|2016Cited by 83